Title |
Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHDgenotyping and a review of policy and practice
|
---|---|
Published in |
BMC Pregnancy and Childbirth, February 2014
|
DOI | 10.1186/1471-2393-14-87 |
Pubmed ID | |
Authors |
Julie Kent, Anne-Maree Farrell, Peter Soothill |
Abstract |
Since its introduction in the 1960s Anti-D immunoglobulin (Anti-D Ig) has been highly successful in reducing the incidence of haemolytic disease of the fetus and newborn (HDFN) and achieving improvements to maternal and fetal health. It has protected women from other invasive interventions during pregnancy and prevented deaths and damage amongst newborns and is a technology which has been adopted worldwide. Currently about one third of pregnant women with the blood group Rhesus D (RhD) negative in the UK (approximately 40,000 women per year in England and Wales), receive antenatal Anti-D Ig in pregnancy when they do not require it because they are carrying a RhD negative fetus. Since 1997, a test using cell free fetal DNA (cffDNA) in maternal blood has been developed to identify the genotype of the fetus and can be used to predict the fetal RhD blood group. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Ireland | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 102 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 19 | 19% |
Student > Master | 13 | 13% |
Researcher | 9 | 9% |
Other | 8 | 8% |
Student > Postgraduate | 8 | 8% |
Other | 18 | 18% |
Unknown | 27 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 32 | 31% |
Agricultural and Biological Sciences | 12 | 12% |
Biochemistry, Genetics and Molecular Biology | 9 | 9% |
Nursing and Health Professions | 5 | 5% |
Immunology and Microbiology | 3 | 3% |
Other | 10 | 10% |
Unknown | 31 | 30% |